News

VCS Performs First U.S. UltiSynq™ Implant in an Outpatient Surgery Center

Richmond cardiac electrophysiologist Vivak Master, MD, performed the procedure using Abbott’s FDA-approved defibrillation lead at the VCS Heart & Vascular Ambulatory Surgery Center.

Cardiac electrophysiologist Vivak Master, MD, with the VCS Heart & Vascular Ambulatory Surgery Center team and Abbott representatives. Dr. Master performed the first U.S. implant of Abbott’s UltiSynq™ Defibrillation Lead in an ambulatory surgery center. The procedure also marked the first UltiSynq implant in Virginia.

IMMEDIATE RELEASE

RICHMOND, Va. (November 20, 2026) – Virginia Cardiovascular Specialists (VCS) announced today that cardiac electrophysiologist Vivak M. Master, MD, performed the first U.S. implant of Abbott’s UltiSynq™ Defibrillation Lead in an ambulatory surgery center. Abbott confirmed the national first and said the procedure was also the first UltiSynq implant in Virginia. 

The procedure took place at the VCS Heart & Vascular Ambulatory Surgery Center, which opened in 2023 as Virginia’s first dedicated cardiovascular ambulatory surgery center. VCS performs implantable cardioverter-defibrillator (ICD) procedures weekly at the center, where eligible patients can return home the same day.

In November 2026, the U.S. Food and Drug Administration (FDA) approved Abbott’s UltiSynq™ Defibrillation Lead, designed to deliver both conduction system pacing (CSP) and defibrillation therapy.

Left bundle branch area pacing (LBBAP) is a CSP strategy, aiming to restore the heart’s natural pattern of electrical activation. UltiSynq provides an additional lead option for patients who are candidates for both CSP and defibrillation protection. 

Dr. Master has hosted training programs to share his experience with left bundle branch area pacing. “Some patients who need an implantable defibrillator can also benefit from physiologic pacing, which uses the heart’s natural electrical pathway. The UltiSynq™ Defibrillation Lead gives our team another option for patients who need both physiologic pacing and defibrillation protection,” said Dr. Master.

Dr. Master is one of nine board-certified VCS electrophysiologists who specialize in heart rhythm disorders. The team implants and manages pacemakers, ICDs, and cardiac resynchronization therapy devices, performs device lead extractions in the hospital, and participates in research on new treatments for heart rhythm disorders.

The surgery center earned accreditation from the Accreditation Association for Ambulatory Health Care (AAAHC) in April 2026. Accreditation recognizes that the center meets standards for quality and safety.

“We built our surgery center so more Central Virginia patients could receive advanced cardiac care closer to home,” said Dean E. Caven, MD, president of VCS. “This procedure reflects our ongoing commitment and the work our physicians and team have done to make that possible.”

Clinical Background

Approximately 150,000 implantable cardioverter-defibrillators (ICDs) are implanted in the United States each year.¹

The FDA approval of the UltiSynq™ Defibrillation Lead was supported by results from the ASCEND CSP IDE trial, a prospective, multicenter, global study. Presented as late-breaking data at the Heart Rhythm Society annual meeting in April 2026, the three-month results demonstrated that UltiSynq exceeded all pre-specified primary safety and effectiveness endpoints. Among 205 implant attempts, lead implantation was successful in 98.5% of patients. 86% of patients achieved LBBP or likely LBBP capture. The three-month complication-free rate was 97.5%, exceeding the pre-specified safety performance goal. In the 120 patients who completed defibrillation testing, successful defibrillation was observed in 100%, with 92.5% successfully defibrillated at 20 J. No lead repositioning was required to achieve defibrillation.²

About UltiSynq™ Defibrillation Lead

The UltiSynq Defibrillation Lead is designed for implantation in the left bundle branch area or the right ventricle to deliver both cardiac pacing and defibrillation therapy. It is intended for use with compatible Abbott ICD and CRT-D systems in patients who meet current clinical practice guidelines for ICD or CRT-D implantation.

For important U.S. safety information on UltiSynq, visit: About UltiSynq | Abbott (https://www.cardiovascular.abbott/us/en/hcp/products/cardiac-rhythm-management/leads/ultisynq)

UltiSynq™ Defibrillation Lead

About Virginia Cardiovascular Specialists

Virginia Cardiovascular Specialists (VCS) is Central Virginia’s largest independent cardiology practice, with 39 board-certified cardiologists serving patients across nine locations in the Greater Richmond area and an accredited ambulatory surgery center. For nearly 50 years, VCS has been a trusted leader in preventing, diagnosing, and treating cardiovascular disease. With a long history of bringing advanced diagnostics, innovative treatments and minimally invasive procedures to Central Virginia, VCS continues to advance cardiovascular care in the communities it serves. Visit www.vacardio.com and follow us on Facebook, Instagram, and LinkedIn.

###

VCS Media Contact
Jennifer Yeager
Director of Marketing
Virginia Cardiovascular Specialists
marketing@vacardio.com

References

  1. Schaller RD, et al. Safety and performance of a novel ICD lead for left bundle branch area pacing: Results from the ASCEND CSP trial. Heart Rhythm. 2026.
  2. Yousef, O., et al. Appropriateness of implantable cardioverter-defibrillator device implants in the United States. Heart Rhythm. 2024.

Published November 20, 2026


Recent Posts

»